Tomisa’s battle with scleroderma and pulmonary fibrosis motivated her to get involved advocating for these diseases.

The thought of having one or both lungs replaced may sound overwhelming, but it's improved the lives of thousands of people ...

According to DataM Intelligence, "The Scleroderma Market Size reached US$ 2,384.73 million in 2024 and is expected to expand to US$ 4,103.07 ...

Today, in honor of World Oxygen Day (October 2), leading patient, provider, and professional organizations are amplifying the voices of people on supplemental oxygen to stress the critical importance ...

Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters ...

In addition to the global Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis, a major form of ILD, efzofitimod is also being investigated in the Phase 2 EFZO-CONNECT study in ...

Detailed price information for Atyr Pharma Inc (ATYR-Q) from The Globe and Mail including charting and trades.

Contineum Therapeutics Inc. has described lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of cancer, idiopathic pulmonary fibrosis, renal fibrosis, ...

UVA Health lung researchers are developing a promising approach to detecting patients at risk of interstitial lung disease (ILD), an increasingly common condition that is a leading reason for lung ...

The prevalence of T2D among a cohort of patients in Italy with SSc was lower than national estimates and associated with distinct vascular and cardiopulmonary features.

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and irreversible lung disease associated with poor quality of ...